Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 25/04/24 | Antibe Announces Appointment of Receiver | BU |
| 23/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/3/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 8/3/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 8/3/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| +2.24% | +5.83% | +58.47% | +65.65% | 66.7B | |
| +4.66% | +8.90% | +14.57% | +85.41% | 56.88B | |
| -0.60% | +1.73% | +23.48% | +94.40% | 56.53B | |
| +2.91% | +15.86% | +27.14% | +120.82% | 46.49B | |
| +2.83% | +7.79% | +30.76% | +45.16% | 44.8B | |
| +3.53% | +5.40% | +216.16% | +890.66% | 41.59B | |
| -0.47% | +9.60% | +27.53% | +52.88% | 35.35B | |
| +3.80% | -1.00% | +95.20% | +66.79% | 33.29B | |
| +0.64% | +5.31% | -40.02% | +391.50% | 25.1B | |
| Average | +2.01% | +3.29% | +50.37% | +201.47% | 45.19B | |
| Weighted average by Cap. | +2.32% | +3.97% | +51.20% | +179.91% |
Employees
11
